NCT05086952View on ClinicalTrials.gov

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

December 22, 2021

Study Completion Date

February 15, 2022

Conditions
Heart FailureChildren
Interventions
DRUG

Vericiguat (BAY1021189) - Intervention A

Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.

DRUG

Vericiguat (BAY1021189) - Intervention B

Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.

DRUG

Vericiguat (BAY1021189) - Intervention C

Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.

DRUG

Vericiguat (Verquvo, BAY1021189) - Intervention D

Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.

Trial Locations (1)

99084

SocraTec R&D GmbH, Erfurt

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT05086952 - A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately | Biotech Hunter | Biotech Hunter